Related Experiment Videos
Interleukin-2 does not sequester activated lymphocytes into lung lymph of sheep
D M Mahvi1, R L Conhaim, B A Harms
1Department of Surgery, University of Wisconsin-Madison 53792, USA.
The Journal of Surgical Research
|January 1, 1996
Summary
Interleukin-2 (IL-2) treatment increased lung lymph flow but decreased lung lymphocytes, suggesting activated lymphocytes do not cause IL-2-induced pulmonary edema. This finding is crucial for understanding IL-2 toxicity in cancer therapy.
Area of Science:
- Immunology
- Cardiovascular Physiology
- Oncology
Background:
- Interleukin-2 (IL-2) activates lymphocytes for cancer therapy but causes pulmonary edema.
- Pulmonary toxicity may stem from lymphocytes increasing pulmonary vascular permeability.
Purpose of the Study:
- To investigate if activated lymphocytes increase pulmonary vascular permeability after IL-2 infusion.
- To assess the impact of IL-2 on lymphocyte populations in sheep's blood and lung lymph.
Main Methods:
- Compared lymphocyte counts (total, gamma delta T cells, CD2-positive cells) in peripheral blood and lung lymph of sheep before and after IL-2 infusion.
- Evaluated hemodynamic and lymph dynamic changes, including lymph flow and protein concentration.
Main Results:
- IL-2 increased lung lymph flow and altered hemodynamics but did not affect plasma or lymph oncotic pressure.
- Peripheral blood lymphocyte counts remained unchanged, while lung lymph lymphocyte counts significantly decreased.
- Lymph protein concentration and lymph-to-plasma protein ratio were unaffected by IL-2.
Conclusions:
- The reduction in lung lymphocytes exceeded dilution effects, indicating active sequestration or removal.
- Results suggest that IL-2-induced pulmonary edema is not caused by activated lymphocytes increasing vascular permeability.